Italian association for the study of the liver position statement on SARS-CoV2 vaccination

Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo, Italian Association for the Study of the Liver, Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo, Italian Association for the Study of the Liver

Abstract

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.

Keywords: Chronic liver disease; Sars-CoV-2; Vaccination.

Conflict of interest statement

Declaration of Competing Interest None.

Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

References

    1. Azzi Y., Bartash R., Scalea J. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105:37–55.
    1. McClung N., Chamberland M., Kinlaw K. The advisory committee on immunization practices’ ethical principles for allocating initial supplies of COVID-19 vaccine-United States, 2020. Am J Transplant. 2021;21:420–425.
    1. Polack F.P., Thomas S.J., Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
    1. Baden L.R., Sahly H.M., Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384:403–416. El.
    1. Matz K.M., Marzi A., Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines. 2019;18:1229–1242.
    1. Voysey M., Clemens S.A.C., Madhi S.A. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
    1. Marjot T., Webb G.J., Barritt A.S. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021;6:156–158.
    1. Aggeletopoulou I., Davoulou P., Konstantakis C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27:e1942.
    1. McCashland T.M., Preheim L.C., Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181:757–760.
    1. Härmälä S., Parisinos C.A., Shallcross L. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open. 2019;9
    1. Baluch A., Humar A., Eurich D. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transpl. 2013;13:1026–1033.
    1. Valour F., Conrad A., Ader F. Vaccination in adult liver transplantation candidates and recipients. Clin Res Hepatol Gastroenterol. 2020;44:126–134.
    1. Rubin L.G., Levin M.J., Ljungman P. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–318.
    1. Feldman A.G., Hsu E.K., Mack C.L. The Importance of prioritizing pre and posttransplant immunizations in an era of vaccine refusal and epidemic outbreaks. Transplantation. 2020;104:33–38.
    1. Fagiuoli S., Colli A., Bruno R. Management of infections pre-and post-liver transplantation: report of an AISF consensus conference. J Hepatol. 2014;60:1075–1089.
    1. Gardiner A., Liu K., Bonnichsen M. Immunity to vaccine-preventable viral infections in Australians being evaluated for liver transplantation. Transplantation. 2019;103:2318–2322.
    1. Liu R., Zhao L., Cheng X. Clinical characteristics of COVID-19 patients with hepatitis B virus infection-a retrospective study. Liver Int. 2021;41:720–730.
    1. Butt A.A., Yan P., Chotani R.A. Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. Liver Int. 2021 doi: 10.1111/liv.14804. ; online ahead of print. doi:
    1. Marjot T., Buescher G., Sebode M. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021 doi: 10.1016/j.jhep.2021.01.021. Available at:
    1. Stefan N., Birkenfeld A.L., Schulze M.B. Global pandemics interconnected-obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135–149.
    1. Kim D., Adeniji N., Latt N. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol. 2020 doi: 10.1016/j.cgh.2020.09.027. ; online ahead of print. doi:
    1. Jose R.J., Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8:46–47.
    1. Piano S., Brocca A., Mareso S. Infections complicating cirrhosis. Liver Int. 2018;38:126–133.
    1. Trebicka J., Fernandez J., Papp M. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2020 doi: 10.1016/j.jhep.2020.11.019. ; online ahead of print. doi:
    1. Fernández J., Acevedo J., Wiest R. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–1880.
    1. Arroyo V., Angeli P., Moreau R. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670–685.
    1. Mangalmurti N., Hunter C.A. Cytokine storms: understanding COVID-19. Immunity. 2020;53:19–25.
    1. Piano S., Dalbeni A., Vettore E. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int. 2020;40:2394–2406.
    1. Iavarone M., D'Ambrosio R., Soria A. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–1071.
    1. Marjot T., Moon A., Cook J. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–577.
    1. Sarin S.K., Choudhury A., Lau G.K. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) Hepatol Int. 2020;14:690–700.
    1. Bajaj J.S., Garcia-Tsao G., Biggins S.W. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70:531–536.
    1. Lee Y.R., Kang M.K., Song J.E. Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: a multicenter study in South Korea. Clin Mol Hepatol. 2020;26:562–576.
    1. Berenguer J., Ryan P., Rodríguez-Baño J. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26:1525–1536.
    1. Hashemi N., Viveiros K., Redd W.D. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. Liver Int. 2020;40:2515–2521.
    1. Chan S.L., Kudo M. Impacts of COVID-19 on liver cancers: during and after the pandemic. Liver Cancer. 2020;9:491–502.
    1. Bitterman R., Eliakim-Raz N., Vinograd I. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2
    1. Webb G.J., Marjot T., Cook J.A. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020;5:1008–1016.
    1. Gambato M., Germani G., Perini B., Gringeri E., Feltracco P., Plebani M., Burra P., Russo F.P. A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection. Transpl Int. 2021 doi: 10.1111/tri.13842. Feb 8Epub ahead of print. PMID: 33556199)
    1. Bhoori S., Rossi R.E., Citterio D. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5:532–533.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅